Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.
Hepatobiliary Pancreat Dis Int
; 16(2): 139-146, 2017 Apr.
Article
em En
| MEDLINE
| ID: mdl-28381376
ABSTRACT
BACKGROUND:
The benefits of the application of basiliximab induction therapy in liver transplantation are not clear. The present meta-analysis was to evaluate the pros and cons of basiliximab use in liver transplantation. DATA SOURCES We searched the associated publications in English from July 1998 to December 2015 in the following databases MEDLINE, PubMed, Ovid, EMBASE, Web of Science and Cochrane Library.RESULTS:
Basiliximab significantly decreased the incidence of de novo diabetes mellitus after liver transplantation (RR=0.56; 95% CI 0.34-0.91; P=0.02). Subgroup analysis showed that basiliximab in combination with steroids-free immunosuppressant significantly decreased the incidence of biopsy-proven acute rejection (RR=0.62; 95% CI 0.39-0.97; P=0.04) and new-onset hypertension (RR=0.62; 95% CI 0.42-0.93; P=0.02).CONCLUSIONS:
Basiliximab may be effective in reducing de novo diabetes mellitus. What is more, basiliximab in combination with steroids-free immunosuppressant shows statistical benefit to reduce biopsy-proven acute rejection and de novo hypertension.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Transplante de Fígado
/
Rejeição de Enxerto
/
Sobrevivência de Enxerto
/
Imunossupressores
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article